Ragueneau-Majlessi I - Search Results

1

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE, Huang SM. Zhao P, et al. J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196. J Clin Pharmacol. 2009. PMID: 19246732

2

Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers.

Levy RH, Ragueneau-Majlessi I, Baltes E. Levy RH, et al. Epilepsy Res. 2001 Aug;46(2):93-9. doi: 10.1016/s0920-1211(01)00253-4. Epilepsy Res. 2001. PMID: 11463510 Clinical Trial.

3

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Ragueneau-Majlessi I, et al. Epilepsy Res. 2001 Nov;47(1-2):55-63. doi: 10.1016/s0920-1211(01)00293-5. Epilepsy Res. 2001. PMID: 11673021 Clinical Trial.

4

New antiepileptic drugs: review on drug interactions.

Hachad H, Ragueneau-Majlessi I, Levy RH. Hachad H, et al. Ther Drug Monit. 2002 Feb;24(1):91-103. doi: 10.1097/00007691-200202000-00016. Ther Drug Monit. 2002. PMID: 11805729 Review.

5

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women.

Ragueneau-Majlessi I, Levy RH, Janik F. Ragueneau-Majlessi I, et al. Epilepsia. 2002 Jul;43(7):697-702. doi: 10.1046/j.1528-1157.2002.57701.x. Epilepsia. 2002. PMID: 12102671 Free article. Clinical Trial.

6

Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database.

Levy RH, Hachad H, Yao C, Ragueneau-Majlessi I. Levy RH, et al. Curr Drug Metab. 2003 Oct;4(5):371-80. doi: 10.2174/1389200033489325. Curr Drug Metab. 2003. PMID: 14529369 Review.

7

Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Garnett WR, Schmerler M, Rosenfeld W, Shah J, Pan WJ. Levy RH, et al. J Clin Pharmacol. 2004 Nov;44(11):1230-4. doi: 10.1177/0091270004268045. J Clin Pharmacol. 2004. PMID: 15496640 Clinical Trial.

8

Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.

Ragueneau-Majlessi I, Levy RH, Bergen D, Garnett W, Rosenfeld W, Mather G, Shah J, Grundy JS. Ragueneau-Majlessi I, et al. Epilepsy Res. 2004 Nov;62(1):1-11. doi: 10.1016/j.eplepsyres.2004.06.008. Epilepsy Res. 2004. PMID: 15519127 Clinical Trial.

9

Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.

Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Levy RH, et al. Ther Drug Monit. 2005 Apr;27(2):193-8. doi: 10.1097/01.ftd.0000153403.99478.1f. Ther Drug Monit. 2005. PMID: 15795651 Clinical Trial.

10

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Ragueneau-Majlessi I, et al. Clin Pharmacokinet. 2005;44(5):517-23. doi: 10.2165/00003088-200544050-00005. Clin Pharmacokinet. 2005. PMID: 15871637

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters